WALTHAM, Mass., Oct. 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month. The Company will also exhibit at the American Dietetic Association’s (ADA) Food and Nutrition Conference & Expo in Denver, Colo.
Specific presentation details are as follows:
IDF 20th World Diabetes Congress - Montreal, Canada.
Date: October 20, 2009
Time: 1-2 p.m.
Interleukin Genetics will present a poster titled, “Perilipin, IL-1, ADRB and MCR-4 Gene Variants Identify Bariatric Surgery Patients who are Predisposed to Dyslipidemia,” at the poster discussion session entitled Complications-dyslipidemia. The poster, #D-0809, will highlight findings that suggest genetic polymorphisms in the perilipin, IL-1, ADRB and MCR-4 genes may predispose to abnormal levels of blood lipids and therefore could have clinical utility in the management of obese patients.
American Society of Human Genetics 59th Annual Meeting - Honolulu, HI
Date: October, 21, 2009
Time: 1-2 p.m.
Interleukin Genetics will present a poster titled, “A Polymorphism in the IL1-B Gene is Associated with Vertebral Fracture Independent of Bone Mineral Density.” The poster, #369, will highlight findings that suggest variations in the IL1B, VDR, and ESR1 genes may indicate susceptibility for vertebral fracture or low bone mineral density. These findings should be valuable in guiding medical management of osteoporosis, design of clinical trials of investigational new drugs, as well as guiding preventive treatments for individuals at risk for the disease.
Obesity Society 27th Annual Scientific Meeting - Washington, D.C.
Date: October, 25, 2009
Time: 1-7:30 p.m.
Interleukin Genetics will present a poster titled, “Perilipin, IL-1 and ADRB Gene Variants Identify Bariatric Surgery Patients who are Resistant to Weight Loss under Calorie Restriction in Preoperative Weight Loss Program.” The poster, #322-P, highlights findings which suggest that genetic polymorphisms in perilipin, IL-1 and ADRB genes show strong association with resistance to weight loss under caloric restriction. These genetic risk markers could have important clinical utility in the medical management of obese patients and in the design of optimal weight loss programs.
In addition to the scientific presentations, Interleukin Genetics will exhibit at the following conference.
American Dietetic Association FNCE Meeting - Denver, CO
Date: October 17-20, 2009
Booth #1900
Interleukin Genetics will exhibit at the ADA’s annual Food and Nutrition Conference & Expo, which will demonstrate the latest nutrition science information and foodservice trends. Highlighted at the Company’s Booth will be the new Inherent Health((TM)) Weight Management Genetic Test designed to guide optimal diet and exercise regimens based on genetics.
About Interleukin Genetics
Interleukin Genetics, Inc. develops and markets genetic tests under the Inherent Health(TM) brand that empower consumers to prevent chronic diseases of aging, and provides genetic biomarker expertise to assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.
SOURCE Interleukin Genetics, Inc.
CONTACT: Media: Erin Walsh of Interleukin Genetics, +1-781-419-4707,
ewalsh@ilgenetics.com; or Investor Relations: Stephanie Ascher of Stern
Investor Relations, +1-212-362-1200, stephanie@sternir.com
Web site: http://www.ilgenetics.com/
